We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $1.33B Turnover 22.73%
1-Year Est. Return 864.5%
This Fund
S&P 500
This Quarter Est. Return
+49.54%
1 Year Est. Return
+864.5%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$566M
Cap. Flow
+$243M
Cap. Flow %
18.34%
Top 10 Hldgs %
65.15%
Holding
66
New
12
Increased
17
Reduced
1
Closed
3
Avg Time Held
0.6 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
0.6 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$45.8M
2
QTTB icon
Q32 Bio
QTTB
+$26.3M
3
CAPR icon
Capricor Therapeutics
CAPR
+$24.4M
4
CELC icon
Celcuity
CELC
+$22.1M
5
QURE icon
uniQure
QURE
+$22M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$19.8M
2
SLNO icon
Soleno Therapeutics
SLNO
+$6.7M
3
ALLO icon
Allogene Therapeutics
ALLO
+$2.69M
4
KALV icon
KalVista Pharmaceuticals
KALV
+$411K

Sector Composition

Rank Sector Weight
1 Healthcare 99.78%
2 Consumer Staples 0.22%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KPTI icon
51
Karyopharm Therapeutics
KPTI
$7.26M
$2.96M 0.22%
302,536
– –
2025 Q4
2 quarters
CLNN icon
52
Clene
CLNN
$48M
$2.94M 0.22%
477,515
– –
2025 Q4
2 quarters
SRPT icon
53
Sarepta Therapeutics
SRPT
$1.87B
$2.7M 0.2%
150,000
– –
2025 Q2
4 quarters
MPLT icon
54
MapLight Therapeutics
MPLT
$447M
$2.69M 0.2%
+75,000
New +$2.16M
2026 Q2
0 quarters
NRIX icon
55
Nurix Therapeutics
NRIX
$2.69B
$2.43M 0.18%
100,000
– –
2024 Q4
6 quarters
LBRX icon
56
LB Pharmaceuticals
LBRX
$1.19B
$2.27M 0.17%
70,000
– –
2025 Q3
3 quarters
EDSA icon
57
Edesa Biotech
EDSA
$25.7M
$1.67M 0.13%
+205,000
New +$1.85M
2026 Q2
0 quarters
IVVD icon
58
Invivyd
IVVD
$191M
$1.31M 0.1%
1,500,000
– –
2025 Q4
2 quarters
UPB icon
59
Upstream Bio Inc
UPB
$183M
$1.04M 0.08%
150,000
– –
2025 Q4
2 quarters
MIST icon
60
Milestone Pharmaceuticals
MIST
$98.8M
$893K 0.07%
666,666
– –
2025 Q3
3 quarters
PEPG icon
61
PepGen
PEPG
$173M
$491K 0.04%
272,892
– –
2025 Q3
3 quarters
RGNX icon
62
Regenxbio
RGNX
$461M
$180K 0.01%
15,000
– –
2026 Q1
1 quarter
SRZNW icon
63
DELISTED
Surrozen Inc Warrant
SRZNW
$1.07K ﹤0.01%
66,666
– –
2024 Q4
6 quarters
KALV icon
64
DELISTED
KalVista Pharmaceuticals
KALV
– –
-20,400
Closed -$411K –
SLNO icon
65
DELISTED
Soleno Therapeutics
SLNO
– –
-200,000
Closed -$6.7M –
TERN icon
66
DELISTED
Terns Pharmaceuticals
TERN
– –
-375,000
Closed -$19.8M –
1 2
3

Similar funds

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.33B AUM 29.71% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.33B AUM 27.72% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.33B AUM 37.42% 1-Year Est. Return
MIC
Means Investment Company Bangor, Maine $1.32B AUM 24.33% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.32B AUM 30.92% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $1.33B AUM 1,044.61% 1-Year Est. Return

Boxer Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Boxer Capital Management held 66 positions worth $1.33B, up 74% from $762M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Boxer Capital Management deployed $243M of net new capital in Q2 2026, opening 12 new positions and adding to 17 existing holdings. Its largest new stake was Q32 Bio: 3,149,310 shares worth $40.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Consumer Staples and Miscellaneous.

On the sell side, the largest reduction was Allogene Therapeutics, an estimated $2.69M trimmed.

  • Boxer Capital Management's largest Q2 2026 buy was Q32 Bio: 3,149,310 shares worth $40.1M.
  • Boxer Capital Management added most to Abivax in Q2 2026, an estimated $45.8M increase.
  • Boxer Capital Management's biggest Q2 2026 reduction was Allogene Therapeutics, cutting an estimated $2.69M.
  • Boxer Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $19.8M.
  • Boxer Capital Management's ten largest holdings make up 65% of its $1.33B portfolio in Q2 2026.
  • Boxer Capital Management opened 12 new positions and closed 3 in Q2 2026.
  • Boxer Capital Management's portfolio value rose 74% quarter-over-quarter to $1.33B.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.